XtalPi Launches Kodexia Closed Loop siRNA Platform With Six Programs
XtalPi debuted Kodexia, combining generative AI, first principles RNA modeling, and automated labs for siRNA discovery, while advancing six internal therapeutic programs including IgA nephropathy.
What changed
On 6 October 2026, XtalPi Holdings (HKEX: 2228) debuted Kodexia, which the company describes as the industry's first closed loop small interfering RNA discovery platform combining generative AI, first principles driven biological modeling, and automated experimentation.
Alongside the platform launch, XtalPi said it is advancing six proprietary therapeutic programs, expanding its modality footprint beyond small molecules, antibodies, and peptides into nucleic acid therapeutics.
The lead IgA nephropathy program serves as an early validation case. XtalPi reports the program reached non human primate efficacy data within seven months, showing greater activity and durability than a clinical stage reference molecule targeting the same target. The company expects preclinical candidate selection within a nine month project timeline, faster than a cited industry norm of 12 to 18 months.
Why it matters
siRNA programs live or die on delivery chemistry, off target profiling, and iteration speed. A closed loop stack that feeds wet lab results back into generative models addresses the main failure mode of AI drug design slides: pretty molecules that never survive animal data.
For portfolio strategists, XtalPi pairing a platform announcement with six internal assets signals confidence that RNA modality economics now justify capital allocation alongside small molecule AI stacks.
Who is affected
RNA therapeutics R&D heads should compare Kodexia's closed loop claims against internal design make test cycles for oligo programs.
AI drug discovery vendors face a higher bar to prove time to NHP data, not just in silico affinity metrics.
Investors in HK listed AI biotech should track whether the IgA nephropathy program publishes candidate selection on the stated nine month clock.
What to do next
If you run oligo discovery, benchmark your median cycle from target nomination to NHP readout against XtalPi's seven month IgA nephropathy timeline before renewing external platform contracts.
What to watch
Watch for preclinical candidate selection timing on the IgA nephropathy program, peer disclosure on the five additional proprietary programs, and partnership announcements that license Kodexia outside XtalPi's internal pipeline.
Sources
- Primary. PR Newswire / XtalPi, XtalPi Debuts Kodexia closed loop siRNA platform (6 October 2026). Platform description, program count, and IgA nephropathy timelines.
- Secondary. XtalPi corporate communications via PR Newswire release (6 October 2026). Corroborating modality expansion and automated experimentation claims.